We are proud to announce the transition of Dendreon to a standalone company. Through this transition, we look forward to building on the great progress we’ve made in the effort to help more men with advanced prostate cancer live longer.
PROVENGE® (sipuleucel-T) is a prescription medicine that is used to treat certain patients with advanced prostate cancer. PROVENGE is made from your own immune cells.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for full Prescribing Information.
As a company, we plan to focus on our priorities of expanding access to PROVENGE® (sipuleucel-T), both in the United States and around the world, conducting further clinical studies, and investigating personalized immunotherapies for other forms of cancer.
Expanding access to PROVENGE in the US and entering new global markets.
Investigating clinical applications for PROVENGE in earlier-stage prostate cancer.
Building on our success and developing our therapeutic platform for other oncology indications.
We are committed to improving the lives of men living with prostate cancer, with the goal of ultimately helping to cure it altogether. Our new path ahead will allow us to accelerate our efforts, reach more patients, and invest in further research.
Partnerships are necessary in the fight against cancer. We stand behind the medical community by providing personalized immunotherapy to deploy as they seek to deliver the best care for their patients.
To date, more than 20,000 men with metastatic, late-stage prostate cancer have been treated with PROVENGE. We’re driven to expand access to more patients and, potentially, to those in earlier stages of the disease.
During and following this transition, Dendreon will continue to operate with the current leadership, manufacturing, operations, scheduling, R&D, and sales teams remaining in place. These teams proved instrumental in turning the business around, and will continue to play critical roles going forward.
Additionally, there will be no disruption or changes to the company’s technology, manufacturing, operations, or distribution process. Product for the United States will continue to be made in the USA.
Our core leadership team:
Chief Executive Officer
Chief Commercial Officer
Chief Operations Officer
With this transition, the Dendreon team that was integral in turning around the business will remain in place and will be bringing with them the expertise and strategic vision needed to build on the momentum we’ve achieved. This opportunity will allow us to bring PROVENGE to more patients in the US and reach new geographies, we’re very excited for what the future holds.
Prostate cancer isn’t bound by national geographies. It’s global – in fact it’s the second most prevalent and deadly cancer in the world. We believe treatments should be global as well, and as a standalone company, we’ll be seeking regulatory approvals to bring PROVENGE to markets around the world.
We’re now prioritizing the necessary resources to advance additional clinical studies of PROVENGE with the ultimate goal of curing more men of prostate cancer. Furthermore, we plan to develop our therapeutic platform for other forms of cancer and seek partnerships to reach more patients in other countries.
Have questions? Looking for more information? Please send inquiries to: email@example.com